BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19769698)

  • 1. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
    Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
    Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
    Lebovitz HE
    J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
    Ma J; Yang W; Fang N; Zhu W; Wei M
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
    Tkác I
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling blood glucose levels in patients with type 2 diabetes mellitus. An evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association.
    Woolf SH; Davidson MB; Greenfield S; Bell HS; Ganiats TG; Hagen MD; Palda VA; Rizza RA; Spann SJ
    J Fam Pract; 2000 May; 49(5):453-60. PubMed ID: 10836779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?].
    Mauricio D; Rius F
    Med Clin (Barc); 2010 Sep; 135 Suppl 2():2-5. PubMed ID: 21420530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-monitoring of blood glucose.
    Garg S; Hirsch IB
    Int J Clin Pract Suppl; 2010 Feb; (166):1-10. PubMed ID: 20377657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control.
    Bailey CJ; Del Prato S; Eddy D; Zinman B;
    Int J Clin Pract; 2005 Nov; 59(11):1309-16. PubMed ID: 16236086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic control and complications in type 2 diabetes mellitus.
    Stolar M
    Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of diabetes in metabolic syndrome].
    Pelikánova T
    Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.